Pleiotropic effects of statins

Acta Cardiologica Sinica

Volumn 21, Issue 4, 2005, Pages 190-198

  Pella, Daniel ^a   Rybar, Rafael ^a   Mechirova, Viola ^a  

^a Med Faculty of Safarik University   (Slovakia)

Author keywords

Atherosclerosis; Pleiotropic effects; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; ENDOTHELIAL DYSFUNCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; PLEIOTROPY; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; THROMBOSIS;

EID: 33644884955     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. World Health Organization. The World Health Report 2002: Reducing risks, promoting healthy life. Geneva: World Health Organization; 2002.
2. American Heart Association. Statistical fact sheet-populations. International Disease Statistics. Dallas, T: American Heart Association; 2003.
3. Endo A, Kuroda M, Tanarawa K. Competitive inhibition of 3-HMG-CoA reductase by ML 236 A and ML 236 B. Febs Lett 1976;72:323-6.
4. Roberts JR. Lipid-lowering drugs in atherosclerosis. Am J Cardiol 1996;89:682.
5. Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;334:1383-9.
6. Sacks FM, Pfeffer MA, Moye LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996;335:1001-9.
7. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Eng J Med 1998;339:1349-57.
8. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of High-risk Groups and Comparison with Other Cardiovascular Intervention Trials. Lancet 1996;346:1339-42.
9. Downs JR, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. N Eng J Med 1999;339:1615-22.
10. Pedersen TR, Olsson AG, Faergeman O, et al. For the Simvastatin Survival Study Group. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-60.
11. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-28.
12. Veillard NR, Mach F. Statins: The new aspirin? Cell Mol Life Sci 2002;59:1771-86.
13. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Eng J Med 2002;346:539-40.
14. ACC/AHA/NHLBI Clinical Advisory on Statins: clinical advisory on the use and safety of statins. JACC 2002;40:567-72.
15. Chong P, Seeger J, Franklin C. Clinically relevant differences between the statins: implications for the therapeutic selection. Am J Med 2000;111:390-400.
16. Chiang CE, Pella D, Singh RB. Coenzyme Q10 and adverse effects of statins. J Nutritional and Environmental Med 2004;14:1-12.
17. Shepherd J. Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety. Eur Heart J 1995;16:5-13.
18. Mason RP, Jacob RF. Membrane microdomains and vascular biology: emerging role in atherogenesis. Circulation 2003;107:2270-3.
19. McKenney JM, Jones PH, Adamczyk MA. For the STELLAR Study Group. Comparison of efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003;19:557-66.
20. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low-density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003;326:1423.
21. Schuster H, Fox JC. Investigating cardiovascular risk reduction: the Rosuvastatin GALAXY Programme. Expert Opin Pharmacother 2004;5:1187-1200.
22. Bevilacqua M, Guazzini B, Righini V, et al. Metabolic effects of fluvastatin extended release 80 mg and atorvastatin 20 mg in patients with type 2 diabetes mellitus and low serum high-density lipoprotein cholesterol levels: a 4-month, prospective, open label, randomised, blinded-end point (Probe) trial. Curr Ther Res 2004;65:330-44.
23. Olsson AG, Schwartz GG, Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005;26:890-6.
24. Davignon J. The pleiotropic effects of drugs affecting lipid metabolism. Atherosclerosis XI. Paris: Elsevier, 1998;63-77.
25. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004;109(suppl III):III-39-III-43.
26. Schoenbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004;109(suppl II):II-18-II-26.
27. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000;101:1899-906.
28. Gokce N, Keaney JF Jr, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002;105:1567-72.
29. Marchesi S, Lupattelli G, Schillaci G, et al. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 2000;36:617-21.
30. Forgione MA, Leopold JA, Loscalzo J. Roles of endothelial dysfunction in coronary artery disease. Curr Opin Cardiol 2000;15:409-15.
31. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Eng J Med 2000;343:1139-47.
32. Cannon CP, Braunwald E, McCabe CH, et al. Comparison of intensive and moderate lipid lowering with statins following acute coronary syndromes. N Eng J Med 2004;350:1495-504.
33. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low-density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 2001;103:1194-7.
34. Weissberg PL. Atherogenesis: current understanding of the causes of atheroma. Heart 2000;83:247-52.
35. Nakagami H, Jensen KS, Liao JK. A novel pleiotropic effect of statins: prevention of cardiac hypertrophy by cholesterol-independent mechanisms. Ann Med 2003;35:398-403.
36. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81.
37. Taylor AJ, Kent SM, Flaherty PJ, et al. ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness. Circulation 2002;106:2055-60.
38. Nissen SE, Tuzcu EM, Schoenhagen P, et al. REVERSAL investigators. Effect of intensive? compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291:1071-80.
39. Kaski JC. Infection, endothelial dysfunction, and atherogenesis. Circulation 2003;108:E171-2.
40. Callahan AS 3rd. Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms. Curr Atheroscler Rep 2003;5:33-7.
41. Borghi C, Dormi A, Veronesi M, et al. Association between different lipid-lowering treatment strategies and blood pressure control in the Brisighella Heart Study. Am Heart J 2004;148:285-92.
42. Levy Y. Beyond cholesterol lowering: effect of statins on markers of cardiovascular disease. Isr Med Assoc J 2004;6:490-1.
43. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001;103:926-33.
44. Singh, RB, Pella D, Chopra BP, et al. Overview of ubiquinone, in memory of a champion, Dr. Emile G. Bliznakov. J of Nutr and Enviroment Med 2003;13:211-4.
45. Yusuf S. Two decades of progress in preventing vascular disease. Lancet 2002;6:2-3.
46. Pella D, Singh RB, Tomlinson B, et al. Coronary artery disease in developing and newly industrialised countries: a scientific statement of the International College of Cardiology. In: Frontiers in Cardiovascular Health. Boston: Kluwer Academic Publishers, 2003:473-87.
47. Moosmann B, Behl C. Selenoprotein synthesis and side effects of statins. Lancet 2004;363:892-4.
48. Silver MA, Langsjoen PH, Szabo S, et al. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Amer J Cardiol 2004;94:1306-10.
49. Kumar A, Kaur H, Kumar S, et al. Atorvastatin alone/in combination with coenzyme Q10 in 103 cases of heart failure due to ischemic cardiomyopathy. In: Abstract book from the Fourth Conference of the International Coenzyme Q10 Association. Los Angeles 2005:54-6.
50. Nash DB, Nash SA. Reclassification of simvastatin to over-the-counter status in the United Kingdom: a primary prevention strategy. Am J Cardiol 2004;94:35F-39F.
51. Doggrell SA. New targets and new drugs down under in 2004. Drug News Perspect 2005;18:149-60.